Literature DB >> 4375683

The depression of phagocytosis by exogenous cyclic nucleotides, prostaglandins, and theophylline.

J P Cox, M L Karnovsky.   

Abstract

The effects of agents that elevate intracellular cyclic adenosine 3',5'-monophosphate (cAMP) have been studied with respect to phagocytosis by guinea pig polymorphonuclear leukocytes. The investigation depends upon the use of a precise method for following ingestion. Theophylline, dibutyryl cAMP, and prostaglandins inhibited the phagocytosis of starch particles. The inhibitions caused by prostaglandins E(1), E(2), and F(2alpha) (PGE(1), PGE(2), and PGF(2alpha)) were synergistic with that due to theophylline. Inhibition by PGA(1) and PGA(2) was not. At equal concentrations the order of increasing inhibition of phagocytosis (assayed at 10 min) by the prostaglandins was PGE(1) < PGF(2alpha) < PGE(2) < PGA(1) = PGA(2). Our results are consistent with the hypothesis that increased intracellular levels of cAMP impair the phagocyte's ability to ingest particles. The mechanism of the inhibition has not been defined. The increment in oxidation of [1-(14)C]glucose to (14)CO(2) that normally accompanies phagocytosis was found to be depressed in the presence of PGE(1) or theophylline, together or individually as expected from the inhibition of phagocytosis. Paradoxically, oxygen consumption although depressed by theophylline or PGE(1) plus theophylline, was stimulated by PGE(1) alone.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4375683      PMCID: PMC2109085          DOI: 10.1083/jcb.59.2.480

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  31 in total

1.  Effects of prostaglandins, epinephrine and NaF on human leukocyte, platelet and liver adenyl cyclase.

Authors:  R E Scott
Journal:  Blood       Date:  1970-04       Impact factor: 22.113

2.  Involvement of adenosine 3',5'-monophosphate in release of ACTH.

Authors:  N Fleischer; R A Donald; R W Butcher
Journal:  Am J Physiol       Date:  1969-11

3.  A comparison of the in-vitro actions of thyroid-stimulating hormone and cyclic 3',5'-adenosine monophosphate on the mouse thyroid gland.

Authors:  J M Ensor; D S Munro
Journal:  J Endocrinol       Date:  1969-03       Impact factor: 4.286

4.  Enthalpy of hydrolysis of the 3' bond of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate.

Authors:  P Greengard; S A Rudolph; J M Sturtevant
Journal:  J Biol Chem       Date:  1969-09-10       Impact factor: 5.157

5.  Stimulation of growth hormone secretion in monkeys by adrenalin, pitressin and adenosine-3'5'-cyclic monophosphoric acid (3'5'-AMP).

Authors:  J J Gagliardino; J M Martin
Journal:  Acta Endocrinol (Copenh)       Date:  1968-11

6.  Effects of compounds which inhibit antigenic release of histamine and phagocytic release of lysosomal enzyme on glucose utilization by leukocytes in humans.

Authors:  C D May; B B Levine; G Weissmann
Journal:  Proc Soc Exp Biol Med       Date:  1970-03

7.  Metabolic and morphological observations on the effect of surface-active agents of leukocytes.

Authors:  R C Graham; M J Karnovsky; A W Shafer; E A Glass; M L Karnovsky
Journal:  J Cell Biol       Date:  1967-03       Impact factor: 10.539

8.  Histamine release in vitro: inhibition by catecholamines and methylxanthines.

Authors:  L M Lichtenstein; S Margolis
Journal:  Science       Date:  1968-08-30       Impact factor: 47.728

9.  Insulin release after ACTH, glucagon and adenosine-3'-5'-phosphate (cyclic AMP) in the perfused isolated rat pancreas.

Authors:  K E Sussman; G D Vaughan
Journal:  Diabetes       Date:  1967-07       Impact factor: 9.461

10.  Measurement of rates of phagocytosis: the use of cellular monolayers.

Authors:  R H Michell; S J Pancake; J Noseworthy; M L Karnovsky
Journal:  J Cell Biol       Date:  1969-01       Impact factor: 10.539

View more
  21 in total

1.  Comparison of leukocyte count and function in smoking and nonsmoking young men.

Authors:  R C Noble; B B Penny
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

2.  Enhanced vesicular transport of exogenous peroxidase across cerebral vessels, induced by serotonin.

Authors:  E Westergaard
Journal:  Acta Neuropathol       Date:  1975       Impact factor: 17.088

3.  Quantitative assessment of tuftsin receptor expression and second messenger during in vitro differentiation of peripheral blood derived monocytes of leprosy patients.

Authors:  S Khare; L K Bhutani; D N Rao
Journal:  Mol Cell Biochem       Date:  1997-06       Impact factor: 3.396

4.  Interaction of polymorphonuclear neutrophils with Escherichia coli. Effect of enterotoxin on phagocytosis, killing, chemotaxis, and cyclic AMP.

Authors:  M J Bergman; R L Guerrant; F Murad; S H Richardson; D Weaver; G L Mandell
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

5.  Metabolic perturbation of the inflammatory cells.

Authors:  F Rossi; D Romeo; P Patriarca
Journal:  Agents Actions       Date:  1976-02

6.  Invasion of HeLa 229 cells by virulent Bordetella pertussis.

Authors:  C A Ewanowich; A R Melton; A A Weiss; R K Sherburne; M S Peppler
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

Review 7.  [Phagocytosis--a central mechanism in inflammatory reaction (author's transl)].

Authors:  J F Kapp
Journal:  Klin Wochenschr       Date:  1978-11-01

8.  Effects of temperature, metabolic inhibitors and some other factors on fluid-phase and adsorptive pinocytosis by rat peritoneal macrophages.

Authors:  M K Pratten; J B Lloyd
Journal:  Biochem J       Date:  1979-06-15       Impact factor: 3.857

9.  Influence of lithium and fluoride on degranulation from human neutrophils in vitro.

Authors:  F J Bloomfield; M M Young
Journal:  Inflammation       Date:  1982-09       Impact factor: 4.092

10.  Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF.

Authors:  M P Hallsworth; M A Giembycz; P J Barnes; T H Lee
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.